Literature DB >> 18403582

Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population.

Lijing Ouyang1, Scott D Grosse, Aileen Kenneson.   

Abstract

We provide estimates of medical care utilization and expenditures for children and young adults younger than age 30 with muscular dystrophies in the United States. Accurate estimates are essential for calculations of lifetime costs and for economic evaluations of screening and management strategies for muscular dystrophy. We compare the medical expenditures for persons with muscular dystrophy with others by age groups. The incremental annual expenditures of medical care for privately insured individuals with muscular dystrophy relative to others in 2004 averaged $18 930 and ranged from $13 464 at ages 5 to 9 to $32 541 at ages 15 to 19. Individuals with muscular dystrophy had average medical expenditures 10 to 20 times greater than individuals without muscular dystrophy. Individuals aged 15 to 19 years had the highest number of inpatient admissions related to respiratory infections and cardiac complications. The findings underscore the need for appropriate treatment options for individuals with muscular dystrophy as they age.

Entities:  

Mesh:

Year:  2008        PMID: 18403582     DOI: 10.1177/0883073808314962

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  19 in total

1.  A national profile of health care and family impacts of children with muscular dystrophy and special health care needs in the United States.

Authors:  Lijing Ouyang; Scott D Grosse; Michael H Fox; Julie Bolen
Journal:  J Child Neurol       Date:  2011-09-27       Impact factor: 1.987

2.  Hospitalizations and emergency room visits for adolescents and young adults with muscular dystrophy living in South Carolina.

Authors:  Joshua R Mann; Julie A Royer; Suzanne Mcdermott; James W Hardin; Orgul Ozturk; Natalie Street
Journal:  Muscle Nerve       Date:  2015-08-14       Impact factor: 3.217

3.  Summary of Selected Healthcare Encounters among a Selection of Patients with Myotonic Muscular Dystrophy.

Authors:  Kevin J Bennett; Joshua R Mann; Lijing Ouyang
Journal:  South Med J       Date:  2019-06       Impact factor: 0.954

4.  Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis.

Authors:  Ilene L Hollin; Holly L Peay; John F P Bridges
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

Review 5.  The paradox of muscle hypertrophy in muscular dystrophy.

Authors:  Joe N Kornegay; Martin K Childers; Daniel J Bogan; Janet R Bogan; Peter Nghiem; Jiahui Wang; Zheng Fan; James F Howard; Scott J Schatzberg; Jennifer L Dow; Robert W Grange; Martin A Styner; Eric P Hoffman; Kathryn R Wagner
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-02       Impact factor: 1.784

6.  Cost-Effectiveness of Ventricular Assist Device Destination Therapy for Advanced Heart Failure in Duchenne Muscular Dystrophy.

Authors:  Defne A Magnetta; JaHyun Kang; Peter D Wearden; Kenneth J Smith; Brian Feingold
Journal:  Pediatr Cardiol       Date:  2018-05-17       Impact factor: 1.655

7.  30-day all-cause readmission rates among a cohort of individuals with rare conditions.

Authors:  Kevin J Bennett; Joshua R Mann; Lijing Ouyang
Journal:  Disabil Health J       Date:  2018-09-12       Impact factor: 2.554

8.  Changes in care coordination and health insurance in the population of US children with muscular dystrophy, 2005-2006 and 2009-2010.

Authors:  Jaimie Z Shing; Tiebin Liu; Rodolfo Valdez
Journal:  Int J Care Coord       Date:  2018-12-14

Review 9.  A Journey with LGMD: From Protein Abnormalities to Patient Impact.

Authors:  Dimitra G Georganopoulou; Vasilis G Moisiadis; Firhan A Malik; Ali Mohajer; Tanya M Dashevsky; Shirley T Wuu; Chih-Kao Hu
Journal:  Protein J       Date:  2021-06-10       Impact factor: 2.371

10.  The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia.

Authors:  Scott D Grosse; Sheree L Boulet; Althea M Grant; Mary M Hulihan; Marie E Faughnan
Journal:  Genet Med       Date:  2013-05-23       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.